Drug Profile

DBI 001

Alternative Names: DBI-001

Latest Information Update: 02 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator James Madison University
Developer DermBiont
Class Antibacterials; Antifungals; Skin disorder therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Atopic dermatitis; Onychomycosis; Tinea pedis

Most Recent Events

21 Sep 2022 DermBiont suspends a Phase II trial in Onychomycosis (Topical) in USA due to sponsors decision and not due to safety or site-related matters (NCT05491603)
15 Sep 2022 DermBiont suspends a phase II trial for Atopic dermatitis (In adolescents, In children, In the elderly) in USA (Topical) (NCT05253755)
08 Aug 2022 Phase-II clinical trials in Tinea pedis in USA (Topical) (NCT05493488)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com